Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MAO-B-IN-5 is a potent, selective and orally active MAO-B inhibitor with an IC 50 of 0.204 μM. MAO-B-IN-5 has the research potential in Parkinson's disease (PD) [1].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 59,500 |
5 mg | 在庫あり | ¥ 147,500 |
10 mg | 在庫あり | ¥ 209,500 |
25 mg | 在庫あり | ¥ 314,500 |
50 mg | 在庫あり | ¥ 424,500 |
100 mg | 在庫あり | ¥ 574,000 |
500 mg | 在庫あり | ¥ 1,124,500 |
説明 | MAO-B-IN-5 is a potent, selective and orally active MAO-B inhibitor with an IC 50 of 0.204 μM. MAO-B-IN-5 has the research potential in Parkinson's disease (PD) [1]. |
In vitro | MAO-B-IN-5 (compound D0) (Sf9 cells) has inhibitory activities towards MAO with the IC 50 s of 34.190 μM and 0.204 μM for MAO-A and MAO-B, respectively [1]. |
In vivo | MAO-B-IN-5 demonstrates oral bioavailability (F=13.6%) in rats when administered at doses of 1 mg/kg intravenously (i.v.) and 5 mg/kg orally (p.o.). The pharmacokinetic profile of MAO-B-IN-5 in Sprague-Dawley (SD) rats is detailed, with the compound showing a maximum concentration (Cmax) of 809 ng/mL and an area under the curve (AUC) of 347 ng·h/mL following a 1 mg/kg intravenous dose; the half-life (T1/2) is 0.37 hours, volume of steady state (Vss) is 1.11 h, and clearance (Cl) is 47.1 mL/min/kg. Orally administered at a dose of 5 mg/kg, MAO-B-IN-5 has a Cmax of 163 ng/mL, an AUC of 284 ng·h/mL, and a T1/2 of 1.27 hours, with an oral bioavailability of 16.3%. |
分子量 | 328.38 |
分子式 | C19H21FN2O2 |
CAS No. | 849909-77-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MAO-B-IN-5 849909-77-9 MAO B IN 5 MAOBIN5 Inhibitor inhibitor inhibit